University of Strathclyde Spinout OpenCMC Accelerates Pharma Manufacturing Revolution

The University of Strathclyde has launched OpenCMC™, an ambitious spinout venture designed to commercialise cutting-edge advanced chemistry manufacturing and digital medicines technologies emerging from its world-renowned CMAC (Continuous Manufacturing and Crystallisation) research centre. The venture-client model represents a significant step forward in bridging the persistent gap between laboratory innovation and industrial-scale pharmaceutical production—a challenge that has long constrained UK drug manufacturing competitiveness.

As Scotland continues to establish itself as a hub for life sciences innovation and advanced manufacturing, OpenCMC's launch signals growing momentum in the country's digital medicines and pharma tech ecosystem. The spinout aligns with UK government priorities to strengthen domestic pharmaceutical manufacturing capabilities and reduce reliance on international supply chains—priorities that have become even more critical following post-Brexit supply chain pressures and global health security concerns.

What Is OpenCMC? The Venture-Client Model Explained

OpenCMC operates on a venture-client model, a relatively novel approach in the UK pharmaceutical innovation landscape. Rather than developing a single proprietary product, the spinout commercialises a suite of digital manufacturing technologies and process innovations derived from two decades of CMAC research. These technologies enable pharmaceutical companies to transition from batch manufacturing—the traditional, time-intensive approach—to continuous manufacturing processes that are faster, more efficient, and more sustainable.

The CMAC centre, based at the University of Strathclyde in Glasgow, has spent over 20 years pioneering research into continuous manufacturing, crystallisation science, and process automation. CMAC is an Engineering and Physical Sciences Research Council (EPSRC) Centre for Doctoral Training and a hub for UK pharmaceutical innovation. Its research underpins manufacturing strategies that major global pharmaceutical companies are now adopting to improve productivity and reduce costs.

OpenCMC's role is to translate CMAC's academic discoveries into commercial tools, software platforms, and consulting services that pharmaceutical manufacturers can deploy immediately. This approach sidesteps the lengthy product development cycle typical of pure biotech spinouts, allowing the venture to generate revenue and impact within months rather than years.

Advanced Manufacturing and Digital Medicines: Scotland's Competitive Edge

Scotland has long been a centre for pharmaceutical research and development. However, the country's role in manufacturing has historically been secondary. OpenCMC's launch represents an opportunity to shift that narrative by positioning Scotland as a leader in next-generation medicines manufacturing—a sector increasingly driven by digital technologies, artificial intelligence, and process automation.

The global advanced pharmaceutical manufacturing market is expanding rapidly. According to industry analysts, the global pharmaceutical manufacturing technology market was valued at approximately $22 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 9-11% through 2030. Continuous manufacturing technologies are a key growth driver, particularly as regulatory bodies including the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have become increasingly supportive of continuous processes.

Within the UK context, advanced manufacturing in life sciences is a cornerstone of the government's Life Sciences Vision, which sets ambitious targets for UK life sciences sector growth. The Department for Science, Innovation and Technology (DSIT) has made clear that pharmaceutical manufacturing innovation—including digital medicines and smart manufacturing—is critical to the UK's long-term competitiveness and supply chain resilience.

Scotland's university research base provides a natural advantage. Beyond Strathclyde, institutions including the University of Edinburgh, University of Glasgow, and Heriot-Watt University are investing heavily in advanced manufacturing research. OpenCMC's launch creates a commercialisation pathway that could accelerate technology transfer from these institutions into industry, generating jobs and intellectual property within Scotland.

CMAC's Research Legacy: From Laboratory to Commercial Application

To understand OpenCMC's significance, it is essential to recognise the depth and breadth of CMAC's research output. The centre was established with EPSRC funding to address a critical challenge in pharmaceutical manufacturing: the inefficiency and inflexibility of traditional batch processes.

Traditional batch manufacturing involves producing drugs in large, discrete batches—a process that can take weeks or months per batch, require extensive cleaning between batches, and generate significant waste. Continuous manufacturing, by contrast, operates on a flow-based principle where raw materials continuously enter a production system, undergo chemical transformation, and emerge as finished product in a seamless stream. The benefits are substantial:

  • Speed: Continuous processes can reduce production time from weeks to days or hours.
  • Efficiency: Reduced waste, lower energy consumption, and optimised resource utilisation.
  • Quality: Real-time process monitoring enables tighter control of product specifications.
  • Flexibility: Continuous systems can be reconfigured more rapidly than batch facilities to produce different medicines.
  • Sustainability: Lower energy use and waste generation align with ESG objectives and regulatory pressures around pharmaceutical sustainability.

CMAC's research has encompassed crystallisation science (controlling how drug molecules arrange themselves into crystal structures), flow chemistry (chemical reactions in microfluidic systems), process automation, data analytics, and regulatory strategy. The centre has trained hundreds of doctoral students and early-career researchers, many of whom have moved into industry roles, creating a network of CMAC alumni within UK pharmaceutical companies.

OpenCMC now formalises the commercialisation of this intellectual capital. The spinout has access to CMAC's research infrastructure, expertise, and relationships with major pharmaceutical partners who have been collaborating with CMAC for years.

The Venture-Client Model: Why It Works for Pharma Tech

OpenCMC's venture-client structure differs from traditional spinout models in important ways. Rather than building a single product and seeking venture funding to develop it into a scalable business, OpenCMC acts as a service and technology provider to multiple clients simultaneously. This model has several advantages:

Revenue From Day One: The spinout can begin generating revenue by offering consulting services, process development, and technology licensing to pharmaceutical manufacturers who are already seeking to adopt continuous manufacturing. There is no waiting period for a product to reach market.

Risk Diversification: Instead of betting on a single drug, molecule, or manufacturing platform, OpenCMC diversifies risk across multiple clients and use cases. If one client's manufacturing project encounters delays, others continue to generate revenue.

Rapid Scaling: The venture-client model allows OpenCMC to scale quickly by acquiring more clients and expanding its service offering, rather than requiring massive capital investment in manufacturing infrastructure.

Data and Learning: Working with multiple pharmaceutical manufacturers across different therapeutic areas and molecules generates rich data about what works in continuous manufacturing. This learning feeds back into improved technologies and services.

The venture-client model is not entirely new in biotech, but it remains relatively uncommon in UK pharmaceutical spinouts. Success will depend on OpenCMC's ability to translate CMAC's academic strengths into practical tools and services that busy manufacturing teams can implement with minimal disruption to existing operations.

Market Opportunity: Digital Medicines and Industry 4.0

OpenCMC's launch arrives at a pivotal moment for pharmaceutical manufacturing. Major pharmaceutical companies are under intense pressure to improve productivity and reduce costs, particularly as many blockbuster drugs lose patent protection and generic competition increases. Simultaneously, regulatory bodies are pushing the industry toward greater sustainability and supply chain transparency.

The convergence of these pressures is driving adoption of Industry 4.0 principles in pharmaceuticals—concepts including real-time process monitoring, data analytics, artificial intelligence, and networked manufacturing systems. Digital medicines manufacturing, the integration of digital technologies into pharmaceutical production, is no longer a futuristic concept; it is an immediate competitive necessity.

Global pharmaceutical leaders including GSK, Roche, Pfizer, and others have publicly committed to continuous manufacturing adoption. These commitments translate into substantial contracts for technology providers, consulting firms, and equipment manufacturers. OpenCMC is positioned to capture a portion of this opportunity by offering specialised expertise in continuous manufacturing process development and optimisation.

Within the UK, companies like Clyde Space have demonstrated how Scottish tech companies can scale globally by focusing on niche, high-value market segments. OpenCMC has the potential to follow a similar trajectory in pharma manufacturing technology.

Regulatory Pathways: EMA, FDA, and MHRA Approval for Continuous Manufacturing

A critical advantage of OpenCMC's timing is that regulatory pathways for continuous manufacturing are now well-established. Both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have published guidance documents supporting continuous manufacturing approaches, and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has adopted aligned positions.

This regulatory clarity removes a major barrier that existed even five years ago. Pharmaceutical companies no longer need to question whether regulators will approve medicines made using continuous processes; the question is simply how to implement such processes effectively. OpenCMC's team can help manufacturers navigate these regulatory requirements, adding significant value beyond the technology itself.

The MHRA, as part of the UK's post-Brexit regulatory framework, has committed to innovation-friendly approaches. The agency has published guidance on continuous manufacturing and digital medicines, creating a supportive environment for companies like OpenCMC that are helping manufacturers adopt these approaches.

University of Strathclyde's Role: Institutional Support and IP Access

The University of Strathclyde has been highly supportive of OpenCMC's launch, providing access to CMAC's research infrastructure, faculty expertise, and intellectual property. This institutional support is critical. Spinouts that maintain strong connections to their parent universities tend to have higher success rates, as they benefit from continued access to research, talent, and credibility.

Strathclyde is one of the UK's leading universities for engineering and applied science research. Its location in Glasgow, within Scotland's Central Belt, provides proximity to industrial partners, financial services, and other innovation hubs. The university has a track record of supporting successful spinouts across sectors including advanced manufacturing, software, and engineering.

For OpenCMC, institutional support translates into several concrete advantages:

  • Access to CMAC's doctoral training programme, ensuring a pipeline of trained scientists.
  • Collaborative arrangements with CMAC researchers on commercial projects.
  • Use of university facilities for proof-of-concept and pilot-scale manufacturing.
  • Credibility with pharmaceutical partners who value the academic backing.

Competitive Landscape: OpenCMC's Position Within UK Pharma Tech

OpenCMC enters a competitive but growing UK pharmaceutical technology and advanced manufacturing landscape. Competitors include larger, established firms like Synthego and Taboris Robotics, as well as international continuous manufacturing specialists like Glatt (Germany) and IFC Technologies (Denmark).

However, OpenCMC's competitive position rests on distinct advantages. First, its deep connection to CMAC research gives it access to intellectual property and scientific expertise that competitors must either develop independently or licence from external partners. Second, its UK base and alignment with the UK Life Sciences Vision make it attractive to pharmaceutical companies seeking to support domestic innovation and reduce supply chain risk. Third, the venture-client model allows OpenCMC to remain lean and flexible, potentially moving faster than larger, more bureaucratic organisations.

Success will require clear execution: delivering measurable results for early clients, building a reputation for reliability and scientific rigour, and establishing OpenCMC as the go-to partner for companies seeking to implement continuous manufacturing in the UK and European markets.

Funding, Growth, and Next Milestones

OpenCMC's funding structure reflects its venture-client model. Rather than seeking a single large venture capital round, the spinout is funded through a combination of university seed funding, EPSRC support, and contracts with pharmaceutical clients. This approach aligns financial incentives: OpenCMC's growth is directly tied to its ability to deliver value to clients, not to investor exit timelines.

Near-term milestones likely include securing pilot contracts with major pharmaceutical manufacturers, developing proprietary software tools for process modelling and optimisation, and expanding the team with experienced pharmaceutical manufacturing engineers. Longer-term opportunities include expanding into adjacent areas like biopharmaceutical manufacturing (increasingly important for monoclonal antibodies and gene therapies) and building an international client base beyond the UK and EU.

Scottish Enterprise and Highlands and Islands Enterprise, the economic development agencies for Scotland, are likely to be supportive partners, as OpenCMC represents exactly the type of high-value, technology-intensive spinout that these organisations are designed to nurture.

Broader Implications for Scotland's Life Sciences Sector

OpenCMC's launch reflects and accelerates broader trends in Scotland's life sciences sector. Scotland is increasingly recognised not just as a place where life sciences research happens, but as a place where that research is commercialised into profitable businesses. The success of companies like Clyde Space in satellite technology and Alba Orbital in small satellites demonstrates that Scottish spinouts can achieve global scale.

OpenCMC has the potential to become Scotland's flagship advanced manufacturing spinout in pharmaceuticals—a sector where Scotland has deep research strength but limited commercial presence. Success could catalyse further spinouts from Strathclyde, Edinburgh, and Glasgow, each leveraging university research and creating high-value jobs in Scotland.

There are also implications for Scotland's position within the UK life sciences ecosystem. While London and the Southeast dominate UK life sciences investment and employment, Scotland is building a distinctive identity around advanced manufacturing, space technology, and research-intensive sectors. OpenCMC fits this narrative perfectly.

Forward-Looking Analysis: The Future of Pharmaceutical Manufacturing

OpenCMC's emergence onto the commercial stage is symptomatic of a fundamental shift in how medicines will be manufactured in the coming decades. Continuous manufacturing is not a niche approach; it is the future standard for pharmaceutical production. This transition will create enormous opportunities for technology providers, consulting firms, and equipment manufacturers who can help the industry make the shift.

Several broader trends will shape OpenCMC's future opportunity:

Supply Chain Resilience: Post-pandemic and post-Brexit, pharmaceutical companies are prioritising domestic and near-shore manufacturing. UK-based advanced manufacturing technologies will be attractive to companies seeking to strengthen supply chains and reduce geographic concentration of production.

Sustainability Imperatives: Environmental, social, and governance (ESG) objectives are becoming binding regulatory and investor requirements for pharmaceutical companies. Continuous manufacturing, with its lower energy and waste profiles, directly supports these objectives. OpenCMC's technologies help companies meet sustainability targets while improving profitability.

Personalised and Rare Disease Medicines: As pharmaceutical development shifts toward more personalised medicines and therapies for rare diseases, manufacturing processes must become more flexible and smaller-scale. Continuous manufacturing is inherently better suited to these requirements than traditional batch processes.

Artificial Intelligence and Automation: The integration of AI into pharmaceutical manufacturing is accelerating. OpenCMC's software tools and process optimisation services position the company well to incorporate AI-driven capabilities as they mature.

Over the next 5-10 years, continuous manufacturing is likely to shift from being a competitive advantage to being a baseline requirement for companies with significant pharmaceutical portfolios. Companies that have not adopted continuous manufacturing by 2030 will likely be at a substantial competitive disadvantage. This creates a large, sustained market for vendors like OpenCMC.

Conclusion: A Catalyst for Scottish Pharma Innovation

OpenCMC's launch from the University of Strathclyde represents a significant milestone for Scotland's life sciences and advanced manufacturing sectors. The spinout demonstrates how decades of publicly-funded research—in this case, CMAC's work on continuous manufacturing—can be translated into commercial ventures that generate wealth, create jobs, and position Scotland as a leader in emerging technologies.

The venture-client model, while less glamorous than a single breakthrough drug or device, may prove more resilient and scalable than traditional biotech spinouts. By serving multiple pharmaceutical manufacturers across different molecules and therapeutic areas, OpenCMC can generate steady revenue, accumulate valuable data and learning, and expand its service offering over time.

For Scotland's economy, OpenCMC's success would signal that the country is capable of producing not just world-class research, but world-class companies that can compete globally in high-value sectors. For the UK pharmaceutical industry, OpenCMC represents a homegrown solution to a critical challenge: how to modernise manufacturing and improve competitiveness in an increasingly demanding global market.

Investors, industry partners, and policymakers should be watching OpenCMC closely. The spinout has strong fundamentals: robust technology, experienced team, supportive institutional backing, and a large, growing market. If OpenCMC executes effectively in its first 12-24 months, it could become one of Scotland's most significant life sciences successes in recent years and a blueprint for how future university spinouts can create substantial commercial value from academic research.